Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Wall Street Zen upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

A number of other research analysts have also recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price target (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $43.75.

Collegium Pharmaceutical Trading Up 0.2%

NASDAQ:COLL opened at $29.88 on Friday. The firm has a 50 day moving average of $28.63 and a 200 day moving average of $29.52. The stock has a market capitalization of $960.04 million, a price-to-earnings ratio of 24.49 and a beta of 0.63. Collegium Pharmaceutical has a 52 week low of $23.23 and a 52 week high of $42.29. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.50 by ($0.01). The company had revenue of $177.76 million during the quarter, compared to analysts’ expectations of $174.96 million. Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The company’s quarterly revenue was up 22.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.45 EPS. As a group, sell-side analysts anticipate that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In related news, Director John Gordon Freund sold 6,601 shares of the firm’s stock in a transaction on Monday, June 9th. The shares were sold at an average price of $30.62, for a total transaction of $202,122.62. Following the sale, the director now owns 70,658 shares in the company, valued at approximately $2,163,547.96. This trade represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC acquired a new stake in Collegium Pharmaceutical during the fourth quarter valued at $40,000. Wealthquest Corp acquired a new stake in Collegium Pharmaceutical during the first quarter valued at $62,000. Virtus Fund Advisers LLC grew its position in Collegium Pharmaceutical by 30.5% during the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 565 shares during the period. FORA Capital LLC acquired a new stake in Collegium Pharmaceutical during the fourth quarter valued at $223,000. Finally, Aigen Investment Management LP acquired a new stake in Collegium Pharmaceutical during the fourth quarter valued at $230,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.